J. Engelbrecht

GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

Roger A. Nadeau, Jonathan B Sumner, T. Furukawa, 2022, Clinical Research in Cardiology.

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

D. Annane, T. Welte, U. Jaschinski, 2022, The Lancet Respiratory Medicine.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

A. Borobia, H. Schuitemaker, Andrew Gibson, 2022, The Lancet Infectious Diseases.

Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data

Pedro F. Campos, Roger A. Nadeau, Jonathan B Sumner, 2021, BMJ.

GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

Roger A. Nadeau, Jonathan B Sumner, T. Furukawa, 2022, Clinical Research in Cardiology.

Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial

U. Jaschinski, L. Otterspoor, N. Riedemann, 2024, Critical care.

Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients

D. Annane, U. Jaschinski, P. van Paassen, 2023, Intensive Care Medicine Experimental.